A Roadmap From Pharma Innovation to Market

Governments are investing in advanced, AI-enabled domestic pharmaceutical manufacturing. Turning research and innovation into commercial impact requires a clear view of demand, regional assets and gaps, and a roadmap that all partners own. 

A U.S. state's Advanced Pharmaceutical Manufacturing (APM) Tech Hub had received a federal award to develop and scale advanced, AI-enabled domestic pharmaceutical manufacturing.

The Tech Hub needed to: 

• Identify the innovations it could accelerate across the state's biohubs. 
• Understand APM demand, regional assets and system gaps. 
• Build an actionable Innovation-to-Commercialization (I2C) roadmap. 

Sia worked in two phases: 

• Pipeline market analysis and landscape: a statewide landscape analysis identifying innovations from the state's five biohubs that the Tech Hub can accelerate; a clear view of APM demand, regional assets and system gaps; focus areas grounded in regional strengths and peer benchmarks; shared definitions of success across R&D, innovation and commercialization, with a metrics framework aligned to I2C. 
• Roadmap development: interactive workshops to validate and sequence initiatives, refined through partner conversations. 

The Tech Hub gained an actionable Innovation-to-Commercialization framework and roadmap, with finalized targets, ownership and timelines. 

By combining market analysis, stakeholder engagement and practical roadmapping, Sia helps innovation hubs turn research into commercial impact.